October 7, 2021 5:11pm

I also wrote, “investors should take a shot or roll the dice for possible profits or loss as some gains are suspect”

Pre-open indication results: 7 Hits and 3 MISS

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close

A fact and numbers-based narrative


The Dow closed UP +337.95 points (+0.98%); the S&P closed UP +36.21 points (+0.83%) while the Nasdaq closed UP +152.11 points (+1.05%)

 

Henry’omics:

Indexes rallied on Thursday as lawmakers reached a deal to increase the debt ceiling in the short-term,

  • Helping sentiment, weekly jobless claims fell sharply last week.

 

Economic data Docket: U.S. states posted a bigger-than-expected drop in new jobless claims last week ended October 2: 326,000 vs. 348,000 expected and an upwardly revised 364,000 during prior week. Continuing claims, week ended September 25: 2.714 million vs. 2.766 million expected and an upwardly revised 2.811 million during prior week

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Thursday opened positive at 28/5, 1 flat and 1 acquired, stayed positive at the mid-day at 28/5, 1 flat and 1 acquired, ending with a positive close of 22/12 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “buy, sell and switch ticker conditions after multiple negative sessions to expect a wannabe bounce” … https://www.regmedinvestors.com/articles/12128

 

Pre-open indication results: 7 Hits: < CRISPR Therapeutics (CRSP +$1.00), Global Blood Therapeutics (GBT +$2.40), Intellia Therapeutics (NTLA +$5.09), Mesoblast (MESO +$0.09); SELL into Strength:   Voyager Therapeutics (VYGR -$0.03), Regenxbio (RGNX -$0.01), Sage Therapeutics (SAGE -$0.35)> and 3 MISS< Biostage (BSTG +$0.19 – “pumped”), Applied Genetic Technologies (AGTC -$0.02), Fate Therapeutics (FATE -$0.79),

 

Key Metric - volume:

  • Sector volume was LOW with 4 of the 22-upside having higher than the 3-month average volume with INCREASED volume of 1 of 12-downside having higher than the 3-month average volume;

Largest downside volume:

  • Voyager Therapeutics (VYGR -$0.03 – 23.68 m shares traded),

 

The Biostage (BSTG) Chronicles: “For years, U.S. regulators said they never got the transparency they needed into the auditing on Chinese companies because https://www.regmedinvestors.com/articles/12110

  • The “pump/promote” is working…

Thursday closed up +$0.19 with 619 shares traded after Wednesday closed down -$0.02 with 951 shares traded, Tuesday closed down -$0.59 with 957 shares traded following Monday closed up +$0.58 with 2,189 shares traded following an a.m. dive of -$0.46 with 2,018 shares traded.

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 22):

  • Intellia Therapeutics (NTLA +$5.09),
  • Global Blood Therapeutics (GBT +$2.40 after Wednesday’s -$0.40 and Tuesday’s -$0.31),
  • Alnylam Pharmaceuticals (ALNY +$1.83 after Wednesday’s +$2.73, Tuesday’s +$3.33 and Monday’s +$2.34)
  • Editas Medicine (EDIT +$1.49 after Wednesday’s -$0.69, Tuesday’s +$0.94 and Monday’s -$2.62)
  • Vericel (VCEL +$1.26 after Wednesday’s +$0.10, Tuesday’s +$1.85 and Monday’s -$1.34)
  • CRISPR Therapeutics (CRSP +$1.00 after Wednesday’s -$0.50),
  • BioLife Solutions (BLFS +$1.00 after Wednesday’s -$0.34, Tuesday’s -$0.42 and Monday’s -$2.02),
  • Ionis Pharmaceuticals (IONS +$0.43 after Wednesday’s +$0.55, Tuesday’s +$0.46 and Monday’s -$1.24),
  • bluebird bio (BLUE +$0.40 after Wednesday’s +$0.21),

Hammered in today’s market (12 of 12):

  • ReNeuron (RENE.L -$1.50 after Wednesday’s +$1.00)
  • Ultragenyx (RARE -$1.04 after Wednesday’s -$0.63, Tuesday’s +$2.14 and Monday’s -$2.82),
  • Fate Therapeutics (FATE -$0.79 after Wednesday’s -$0.18, Tuesday’s +$0.89 and Monday’s -$3.09)
  • Sage Therapeutics (SAGE -$0.35 after Wednesday’s +$0.62 and Tuesday’s +$0.67),
  • uniQure NV (QURE -$0.12)
  • Precigen (PGEN -$0.03 after Wednesday’s -$0.28),
  • Voyager Therapeutics (VYGR -$0.03 after Wednesday’s +$1.60 and Tuesday’s -$0.09),
  • Applied Genetic Technologies (AGTC -$0.02 after Wednesday’s +$0.07),
  • Bellicum Pharmaceuticals (BLCM -$0.02),
  • Chinook Therapeutics (KDNY -$0.02 after Wednesday’s -$0.26 and Tuesday’s -$0.51),
  • Pluristem (PSTI -$0.01),
  • Regenxbio (RGNX -$0.01 after Wednesday’s +$1.60, Tuesday’s -$1.43 and Monday’s -$7.95)

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed up +1.32% and XBI closed up +1.32%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -1.46 points or -6.95% at 19.54

 

October, the first month of Q3/21:

Thursday closed positive with 22 advancers, 12 decliners and 1 acquired

 

The BOTTOM LINE: I am smiling all the way to the upside … after sudden highs – I am one to say … BYE.

Volume is a somber factor, Wednesday was lower in the sector versus today, Thursday.

  • Yesterday, sector volume was LOW with 1 of the 9-upside having higher than the 3-month average volume with INCREASED volume of 7 of 23-downside having higher than the 3-month average volume;
  • Today, sector volume was LOW with 4 of the 22-upside having higher than the 3-month average volume with INCREASED volume of 1 of 12-downside having higher than the 3-month average volume;

There is still a lot of risk out-there and sentiment is as lonely as volatility.

The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.